Br Biologics Profile
Key Indicators
- Authorised Capital ₹ 2.25 Cr
as on 06-12-2024
- Paid Up Capital ₹ 2.25 Cr
as on 06-12-2024
- Company Age 26 Year, 10 Months
- Last Filing with ROC 31 Mar 2024
- Satisfied Charges ₹ 0.50 M
as on 06-12-2024
- Revenue 407.57%
(FY 2020)
- Profit 54.07%
(FY 2020)
- Ebitda 17.40%
(FY 2020)
- Net Worth 1.04%
(FY 2020)
- Total Assets 0.65%
(FY 2020)
About Br Biologics
The Company is engaged in the Real Estate And Construction Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 2.25 Cr and a paid-up capital of Rs 2.25 Cr.
The company has closed loans amounting to ₹0.50 M, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Surinder Chawla and Bhushan Chawla serve as directors at the Company.
- CIN/LLPIN
U74220DL1998PTC092443
- Company No.
092443
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
26 Feb 1998
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Delhi, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Br Biologics?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Surinder Chawla  | Director | 08-Feb-2021 | Current |
| Bhushan Chawla | Director | 01-Feb-2021 | Current |
Financial Performance of Br Biologics.
Br Biologics Private Limited, for the financial year ended 2020, experienced significant growth in revenue, with a 407.57% increase. The company also saw a substantial improvement in profitability, with a 54.07% increase in profit. The company's net worth moved up by a moderate rise of 1.04%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Br Biologics?
In 2020, Br Biologics had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Calico Polymers Private LimitedActive 24 years 7 monthsSurinder Chawla and Bhushan Chawla are mutual person
- Barkat Raj Infra Private LimitedActive 16 years 8 months
Surinder Chawla and Bhushan Chawla are mutual person
- Kismat Buildcon Private LimitedActive 20 years 10 months
Surinder Chawla and Bhushan Chawla are mutual person
- Chawla Financial Services LimitedActive 29 years 1 month
Surinder Chawla and Bhushan Chawla are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
State Bank Of Mysoore Creation Date: 27 Nov 2003 | ₹0.50 M | Satisfied |
How Many Employees Work at Br Biologics?
Unlock and access historical data on people associated with Br Biologics, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Br Biologics, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Br Biologics's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
